RT Journal Article
SR Electronic
A1 Alexander, Lori
T1 Results of the EXTREME Study
JF MD Conference Express
YR 2007
FD SAGE Publications
VO 7
IS 3
SP 15
OP 15
DO 10.1177/155989770700700308
UL http://mdc.sagepub.com/content/7/3/15.abstract
AB Overall survival for patients with head and neck cancers is significantly prolonged with the addition of cetuximab to platinum-based chemotherapy, according to results of the phase 3 EXTREME study. In addition, adding cetuximab did not increase toxicities above those characteristic of platinum-based therapy.